Definium Therapeutics, Inc.
$23.18
▲
0.39%
2026-04-21 06:24:02
definiumtx.com
NMS: DFTX
Explore Definium Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.26 B
Current Price
$23.18
52W High / Low
$23.41 / $5.36
Stock P/E
—
Book Value
$3.36
Dividend Yield
—
ROCE
-44.54%
ROE
-64.06%
Face Value
—
EPS
$-2.06
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
105
Beta
2.56
Debt / Equity
12.21
Current Ratio
6.29
Quick Ratio
6.29
Forward P/E
-12.4
Price / Sales
—
Enterprise Value
$1.78 B
EV / EBITDA
-10.68
EV / Revenue
—
Rating
None
Target Price
$35.23
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Corbus Pharmaceuticals Holdings, Inc. | $10.62 | — | $188.36 M | — | -57.84% | -54.18% | $20.56 / $5.75 | $8.38 |
| 2. | Virax Biolabs Group Limited | $0.14 | — | $1.05 M | — | -107.11% | -83.82% | $1.2 / $0.1 | $0.81 |
| 3. | Larimar Therapeutics, Inc. | $4.81 | — | $499.68 M | — | -212.84% | -1.33% | $6.42 / $1.73 | $0.94 |
| 4. | Xilio Therapeutics, Inc. | $8.45 | — | $49.46 M | — | -42.66% | -1.33% | $16.52 / $6.47 | $7.79 |
| 5. | Polaryx Therapeutics, Inc. | $5.7 | — | $289.74 M | — | -171.33% | -1.94% | $48.91 / $2.2 | $0.1 |
| 6. | SAB Biotherapeutics, Inc. | $3.86 | 14.78 | $196.16 M | — | -30.19% | 14.96% | $6.6 / $1.3 | $3.18 |
| 7. | Achieve Life Sciences, Inc. | $4.25 | — | $226.27 M | — | -167.79% | -2.58% | $6.03 / $1.95 | $0.4 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -47.58 M | -45.67 M | -40.9 M | -32.16 M | -32.46 M | — |
| Net Profit | -50.44 M | -67.27 M | -42.74 M | -23.35 M | -34.74 M | — |
| EPS in Rs | -0.51 | -0.67 | -0.43 | -0.23 | -0.35 | -0.27 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -166.31 M | -103.92 M | -93.87 M | -66.33 M |
| Net Profit | -183.79 M | -108.68 M | -95.73 M | -56.8 M |
| EPS in Rs | -1.84 | -1.09 | -0.96 | -0.57 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 440.1 M | 302.15 M | 124.54 M | 169.99 M |
| Total Liabilities | 107.77 M | 60.7 M | 46.41 M | 19.08 M |
| Equity | 332.33 M | 241.45 M | 78.13 M | 150.92 M |
| Current Assets | 419.32 M | 281.62 M | 103.87 M | 146.06 M |
| Current Liabilities | 66.7 M | 38.85 M | 32.25 M | 17.89 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -131.56 M | -79.13 M | -64.36 M | -50.14 M |
| Investing CF | -151.61 M | 0 M | — | 0 M |
| Financing CF | 267.27 M | 253.2 M | 21.85 M | 59.05 M |
| Free CF | -131.56 M | -79.13 M | -64.36 M | -50.14 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -13.52% | -68.55% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2022-08-29 | 1:0.0666667 |